J
Jan Budczies
Researcher at University Hospital Heidelberg
Publications - 185
Citations - 16222
Jan Budczies is an academic researcher from University Hospital Heidelberg. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 48, co-authored 166 publications receiving 12762 citations. Previous affiliations of Jan Budczies include German Cancer Research Center & Humboldt University of Berlin.
Papers
More filters
Journal ArticleDOI
Updating the risk profile of fatal head trauma: an autopsy study with focus on age- and sex-dependent differences
Katharina Kronsbein,B. Karger,Jan Budczies,Heidi Pfeiffer,Daniel Wittschieber,Daniel Wittschieber +5 more
TL;DR: Investigation of the circumstances and injury patterns of FHT with particular focus on age and sex, and a recent risk profile of F HT, found that FHT still occurs predominantly in male individuals under the age of 45 years, in the context of traffic accidents and affected by alcohol intake.
Proceedings ArticleDOI
Abstract 5573: GC-TOF mass spectroscopy reveals strong dependence of breast cancer metabolome on estrogene receptor, but not on HER2 status
Jan Budczies,Carsten Denkert,Berit Maria Müller,Manfred Dietel,Cornelia Radke,Jules L. Griffin,Matej Orešič,Gert Wohlgemut,Oliver Fiehn +8 more
TL;DR: It is shown that metabolic profiling of fresh-frozen breast cancer samples with GC-MS is feasible and a strong dependence of the metabolite patterns on ER status, but no dependence on HER2 status is detected.
Journal ArticleDOI
Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer: A genome-based investigation in the neoadjuvant GeparSepto trial.
Carsten Denkert,Michael Untch,Stephen C. Benz,Karsten Weber,Justin Golovato,Jan Budczies,Valentina Nekljudova,Elmar Stickeler,Rahul Parulkar,Andreas Schneeweiss,Christian Jackisch,J. Zachary Sanborn,B. Conrad,Hermann Wiebringhaus,Jens Huober,Kerstin Rhiem,Patrick Soon-Shiong,Peter A. Fasching,Shahrooz Rabizadeh,Sibylle Loibl +19 more
TL;DR: This work investigates the hypothesis that the individual patterns of mutational signatures determine the clinical behavior of breast cancer (BC) , in particular response to neoadjuvant chemotherapy.
Journal ArticleDOI
[Structure and content of the EU-IVDR : Current status and implications for pathology].
Andy Kahles,H. R. Goldschmid,Anna-Lena Volckmar,Carolin Plöger,Daniel Kazdal,Roland Penzel,Jan Budczies,Gisela Kempny,Marlon Kazmierczak,Christa Flechtenmacher,Gustavo B. Baretton,Wilko Weichert,David Horst,Frederick Klauschen,Ulrich M. Gassner,Monika Brüggemann,Michael Vogeser,Peter Schirmacher,Albrecht Stenzinger +18 more
TL;DR: The European Parliament and the Council of the European Union have proposed a new amending regulation (EU 2017/746) on in vitro diagnostic medical devices (IVDR) which introduces a phased implementation of the IVDR with new transitional provisions for certain in vitro diagnosis medical devices and a later date of application of some requirements for in-house devices for healthcare facilities as mentioned in this paper .
Proceedings ArticleDOI
Abstract P2-09-03: Antitumor activity of the glutaminase inhibitor, CB-839, in triple-negative breast cancer
Matt Gross,Jan Budczies,Susan Demo,Julie Janes,Evan R. Lewis,Francesco Parlati,Andrew L. Mackinnon,Mirna Rodriguez,Jinfu Yang,Frances Zhao,Adam D. Richardson,C Denkert,Oliver Fiehn,Mark K. Bennett +13 more
TL;DR: The TNBC subtype displayed the greatest sensitivity to CB-839 treatment and this sensitivity was correlated with: i) dependence on extracellular Gln for growth (r = 0.83)